Condensed Consolidated Statements Of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Cash Flows from Operating Activities
Net income	$ 1,757	$ 1,026
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	5,951	5,843
Gain on sale of bioplastics manufacturing business	(1,453)	0
Gain on sale of joint venture interest	0	(4,055)
Loss on sale of assets	0	48
Share based compensation	763	419
Equity in (earnings) loss of Joint Ventures	871	(294)
Changes in operating assets and liabilities:
Restricted cash	12	4,848
Receivables, net	4,168	(7,560)
Inventory	(4,575)	(5,443)
Prepaid expenses	(1,145)	(129)
Refundable income taxes	7	52
Accounts payable	(781)	(998)
Accounts payable to affiliate, net	(4,008)	(1,556)
Accrued expenses	1,049	1,058
Change in derivatives	0	(270)
Deferred credit	(175)	(299)
Accrued retirement health and life insurance benefits and other noncurrent liabilities	(480)	(158)
Net cash provided by (used in) operating activities	1,961	(7,468)
Cash Flows from Investing Activities
Proceeds from sale of bioplastics manufacturing business	2,797	0
Proceeds from sale of joint venture interest	0	9,103
Proceeds from the disposition of property and equipment	0	2,232
Additions to property and equipment	(1,757)	(4,245)
Investment in and advances to unconsolidated subsidiaries	0	(500)
Net cash provided by investing activities	1,040	6,590
Cash Flows from Financing Activities
Payments of dividends	(916)	(914)
Principal payments on long-term debt	(855)	(829)
Proceeds from revolving credit facility	59,036	71,095
Principal payments on revolving credit facility	(60,266)	(68,857)
Net cash provided by (used by) financing activities	(3,001)	495
Decrease in cash and cash equivalents	0	(383)
Cash and cash equivalents, beginning of year	0	383
Cash and cash equivalents, end of period	$ 0	$ 0